Molecular subgroups of medulloblastoma: the current consensus
An international consensus divided medulloblastoma into four molecular subgroups, WNT, SHH, group 3 and group 4, with different origins, genetics, ages and survival, a scheme now used in diagnosis and to design risk-adapted trials.
Overview
Consensus paper from medulloblastoma researchers reconciling several transcriptomic classifications into four subgroups (WNT, SHH, group 3, group 4), summarising their demographics, histology, genetics, clinical behaviour and outcomes, and proposing nomenclature for research and clinical use.
- WNT tumours have over 90 percent survival, SHH intermediate outcomes dependent on TP53, group 3 the worst outlook and group 4 intermediate.
The medulloblastoma subtype pages on this site follow this scheme, which entered the WHO classification in 2016 and drives current de-escalation and intensification trials.
- Subgroups have since been split into further subtypes (Cavalli 2017) with prognostic differences.
Similar pages
not linked directly; found by shared links- Key paperIntertumoural heterogeneity within medulloblastoma subgroups
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
- Key paperACNS0331: reduced-dose and reduced-volume radiotherapy with chemotherapy for average-risk medulloblastoma
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH).
- Key paperThe 2021 WHO classification of tumours of the central nervous system: a summary
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
- TermMedulloblastoma molecular groups (WNT, SHH, group 3, group 4)
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
- TreatmentThiotepa
Shares Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
- TrialCOG ACNS0331
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH).
- TreatmentLomustine (CCNU)
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
- InstitutionSt. Jude Children's Research Hospital
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.